Related Experiment Video

Updated: May 3, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

951

Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma

Y Zhang1, J Kim1, A C Mueller2

  • 1Department of Microbiology, Immunology and Cancer Biology, University of Virginia, Charlottesville, VA, USA.

Cell Death and Differentiation
|January 21, 2014
PubMed

Insights

MicroRNA-134 (miR-134) acts as a tumor suppressor in glioblastoma (GBM) by inhibiting cancer cell growth. Its downregulation by receptor tyrosine kinases (RTKs) is a key driver of GBM malignancy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Receptor tyrosine kinases (RTKs) are frequently co-deregulated in glioblastoma (GBM), the most aggressive primary brain tumor.
  • The dysregulation of RTKs significantly contributes to GBM's high mortality rate.

Purpose of the Study:

  • To investigate the role of microRNA-134 (miR-134) in GBM pathogenesis.
  • To elucidate the regulatory relationship between RTKs (MET, EGFR, PDGFR) and miR-134.
  • To determine the functional impact of miR-134 on GBM cell and stem cell behavior.

Main Methods:

  • Analysis of miR-134 expression in human GBM tumors and cancer stem cells.
  • Correlation studies between RTK activation and miR-134 levels.
  • In vitro and in vivo experiments to assess miR-134's effects on cancer cell proliferation, survival, self-renewal, and xenograft growth.
  • Identification of miR-134 target genes (KRAS, STAT5B).
  • Investigation of molecular pathways (MAPK signaling, KLF4) involved in RTK-mediated regulation of miR-134.

Main Results:

  • miR-134 is downregulated in GBM tumors and cancer stem cells, inversely correlating with MET, EGFR, and PDGFR activation.
  • miR-134 suppresses GBM cell and stem cell proliferation, survival, self-renewal, and xenograft growth.
  • KRAS and STAT5B are identified as direct targets of miR-134.
  • miR-134 induction is essential for the anti-tumor activity of RTK inhibitors.
  • MAPK signaling and KLF4 mediate RTK-driven downregulation of miR-134.

Conclusions:

  • miR-134 functions as a novel tumor-suppressive hub in GBM, regulated by RTKs.
  • The RTK-miR-134-KRAS/STAT5B axis is a critical determinant of GBM malignancy.
  • Targeting this axis, potentially through miR-134 induction, holds therapeutic potential for GBM.

More Related Videos

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.2K
Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome07:23

Describing a Transcription Factor Dependent Regulation of the MicroRNA Transcriptome

Published on: June 15, 2016

7.6K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
4.7K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.4K